Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Lunresertib
RP-6306 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RP-6306 + Gemcitabine | ACTIVE_COMPARATOR | - |
| RP-6306 + FOLFIRI | ACTIVE_COMPARATOR | - |
| RP-6306 + Trastuzumab | ACTIVE_COMPARATOR | - |
| RP-6306 + RP-3500 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| RP-6306 | DRUG | Dose and schedule will be assigned at enrolment |
| Gemcitabine | DRUG | Dose and schedule will be assigned at enrolment |
| FOLFIRI Protocol | DRUG | Irinotecan Leucovorin FU |
| Trastuzumab | DRUG | standard doses q3weekly |
| RP-3500 | DRUG | Dose and schedule will be assigned at enrolment |
Inclusion Criteria: * Patients must have histologically confirmed cancer, that is advanced/metastatic/recurrent or unresectable, for which no curative therapy exists, and be eligible for one or more of the open cohorts * All patients must have a formalin fixed paraffin embedded tissue block (from p...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
RP-6306 is an investigational small molecule drug being developed by Repare Therapeutics Inc. for the treatment of advanced cancer. It is a biomarker-selected therapy, meaning it is studied in patients whose tumors carry specific molecular features. RP-6306 is currently in Phase 2 clinical development and has not been approved by the FDA.
RP-6306 targets WEE1, a kinase enzyme involved in regulating the cell cycle and DNA damage response. By inhibiting WEE1, RP-6306 is designed to interfere with how cancer cells manage DNA damage and cell division. WEE1 inhibition is being explored as a strategy in biomarker-selected advanced cancers.
RP-6306 is being developed by Repare Therapeutics Inc., a clinical-stage precision oncology company. Repare Therapeutics trades on the Nasdaq under the ticker symbol RPTX. The company focuses on targeted cancer therapies directed at specific genetic vulnerabilities in tumors.
RP-6306 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. The Phase 2 trial evaluating RP-6306 in patients with advanced cancer has been completed.
RP-6306 has been evaluated in one clinical trial, NCT05605509, titled "RP-6306 in Patients With Advanced Cancer." This Phase 2 trial enrolled 28 patients with advanced cancer in Canada, was active-controlled, and did not use randomization or double-blinding. The trial has been completed.